IO Biotech Inc

NASDAQ IOBT

Data sourced from

and

Download Data

IO Biotech Inc Free Cash Flow for the year ending December 31, 2023: USD -72.06 M

IO Biotech Inc Free Cash Flow is USD -72.06 M for the year ending December 31, 2023, a -19.27% change year over year. Free Cash Flow is the cash flow available to a company after deducting capital expenditures from operating cash flow, indicating its ability to generate cash for expansion, debt repayment, or dividends.

IO Biotech Inc Free Cash Flow for the year ending December 31, 2022 was USD -60.42 M, a -48.09% change year over year.
IO Biotech Inc Free Cash Flow for the year ending December 31, 2021 was USD -40.80 M, a -309.79% change year over year.
IO Biotech Inc Free Cash Flow for the year ending December 31, 2020 was USD -9.96 M, a -11.98% change year over year.
IO Biotech Inc Free Cash Flow for the year ending December 31, 2019 was USD -8.89 M.

NASDAQ: IOBT

IO Biotech Inc

CEO	Dr. Mai-Britt Zocca Ph.D.
IPO Date	Nov. 5, 2021
Location	Denmark
Headquarters	Ole Maaløes Vej 3, Copenhagen, Denmark, 2200
Employees	68
Sector	Healthcare
Industry	Biotechnology

Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Key trends